Not yet a member?Join now!|Lost password
12/10/2012 | Press release
distributed by noodls on 12/10/2012 02:19
Fresenius Medical Care AG & Co. KGaA ("the company" or "Fresenius Medical Care"), the world's largest provider of dialysis products and services, announced today the appointment of Dr. Olaf Schermeier (40) as chief officer of global research and development (R&D) and member of the management board. He will start in his new position on March 1, 2013.
Dr. Schermeier has many years of experience in various areas of the health care industry. Since 2004 he has served in senior research and development positions and currently serves as president of global R&D for Draeger Medical, Lübeck, Germany. In this capacity he leads the organization's global product development for respiratory therapy, anesthesia, warming therapy, patient monitoring and clinical IT. He was also responsible for reorganizing the company's R&D efforts into one global R&D organization. Dr. Schermeier holds a doctorate degree (PhD) in Computer Science from the Technical University of Berlin, Germany and graduated from the University of Hannover, Germany in Electrical Engineering.
Rice Powell, chief executive officer of Fresenius Medical Care effective January 1, 2013, said: "It is important for our future to continue to ensure market-oriented product innovations and improvements. At the same time we have to further increase the efficiency of our processes on a global basis. For this reason, we created the new role chief officer of global R&D. Olaf Schermeier's depth of global experience with Draeger Medical will provide us with some superb knowledge in this respect. We are fortunate to have a person as qualified as Olaf Schermeier and we are looking forward to working with him in this role".
Note to the media: An image of Dr. Schermeier can be found at: http://www.fresenius.com/3926_4572.htm